Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and sotrastaurin

sorafenib has been researched along with sotrastaurin in 2 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(sotrastaurin)		Trials
(sotrastaurin)		Recent Studies (post-2010) (sotrastaurin)
6,5207305,251881269

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)sotrastaurin (IC50)
Serine/threonine-protein kinase D3Homo sapiens (human)0.0021
Tyrosine-protein kinase ABL1Homo sapiens (human)3.3
Protein kinase C beta typeHomo sapiens (human)0.0025
Tyrosine-protein kinase FynHomo sapiens (human)5.5
Cytochrome P450 3A4Homo sapiens (human)0.001
Serine/threonine-protein kinase pim-1Homo sapiens (human)0.0501
Protein kinase C alpha typeHomo sapiens (human)0.0026
Cyclin-A2Homo sapiens (human)2.3
Tyrosine-protein kinase JAK1Homo sapiens (human)7.3
Protein kinase C eta typeHomo sapiens (human)0.0041
Cyclin-dependent kinase 2Homo sapiens (human)2.3
Tyrosine-protein kinase receptor UFOHomo sapiens (human)9.1
Vascular endothelial growth factor receptor 3Homo sapiens (human)4.6
Vascular endothelial growth factor receptor 2Homo sapiens (human)3.9
Glycogen synthase kinase-3 betaHomo sapiens (human)0.87
Tyrosine-protein kinase JAK3Homo sapiens (human)1.5
Protein kinase C beta type Mus musculus (house mouse)0.234
Cyclin-A1Homo sapiens (human)2.3
Protein kinase C epsilon typeHomo sapiens (human)0.0041
Protein kinase C theta typeHomo sapiens (human)0.0094
Focal adhesion kinase 1Homo sapiens (human)8.3
Protein kinase C zeta typeHomo sapiens (human)5.4
Protein kinase C delta typeHomo sapiens (human)0.0025
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)0.0031
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrialHomo sapiens (human)6.7

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1

Other Studies

2 other study(ies) available for sorafenib and sotrastaurin

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017